Literature DB >> 15591497

Resistance to lamivudine therapy: is there more than meets the eye?

G Dusheiko1, A Bertoletti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15591497      PMCID： PMC1774354          DOI： 10.1136/gut.2004.047548

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  21 in total

1.  Viral features of lamivudine resistant hepatitis B genotypes A and D.

Authors:  Bernhard Zöllner; Jörg Petersen; Elisabeth Puchhammer-Stöckl; Josef Kletzmayr; Martina Sterneck; Lutz Fischer; Matthias Schröter; Rainer Laufs; Heinz-Hubert Feucht
Journal:  Hepatology       Date:  2004-01       Impact factor: 17.425

Review 2.  How will we use the new antiviral agents for hepatitis B?

Authors:  Robert P Perrillo
Journal:  Curr Gastroenterol Rep       Date:  2002-02

3.  Durability of serologic response after lamivudine treatment of chronic hepatitis B.

Authors:  Jules L Dienstag; Janusz Cianciara; Selim Karayalcin; Kris V Kowdley; Bernard Willems; Stanilav Plisek; Mary Woessner; Stephen Gardner; Eugene Schiff
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

4.  Immunogenicity and tolerogenicity of hepatitis B virus structural and nonstructural proteins: implications for immunotherapy of persistent viral infections.

Authors:  Kazuhiro Kakimi; Masanori Isogawa; JoSan Chung; Alessandro Sette; Francis V Chisari
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

5.  Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.

Authors:  C Boni; A Bertoletti; A Penna; A Cavalli; M Pilli; S Urbani; P Scognamiglio; R Boehme; R Panebianco; F Fiaccadori; C Ferrari
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

6.  Histological outcome during long-term lamivudine therapy.

Authors:  Jules L Dienstag; Robert D Goldin; E Jenny Heathcote; H W L Hann; Mary Woessner; Sally L Stephenson; Stephen Gardner; D Fraser Gray; Eugene R Schiff
Journal:  Gastroenterology       Date:  2003-01       Impact factor: 22.682

7.  Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated.

Authors:  J Wiegand; J J Tischendorf; B Nashan; J Klempnauer; P Flemming; P Niemann; P Rohde; M P Manns; C Trautwein; H L Tillmann
Journal:  Z Gastroenterol       Date:  2004-01       Impact factor: 2.000

Review 8.  A treatment algorithm for the management of chronic hepatitis B virus infection in the United States.

Authors:  Emmet B Keeffe; Douglas T Dieterich; Steve-Huy B Han; Ira M Jacobson; Paul Martin; Eugene R Schiff; Hillel Tobias; Teresa L Wright
Journal:  Clin Gastroenterol Hepatol       Date:  2004-02       Impact factor: 11.382

9.  Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy.

Authors:  George J M Webster; Stephanie Reignat; David Brown; Graham S Ogg; Louise Jones; Suranjith L Seneviratne; Roger Williams; Geoffrey Dusheiko; Antonio Bertoletti
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

10.  The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis.

Authors:  B Rehermann; P Fowler; J Sidney; J Person; A Redeker; M Brown; B Moss; A Sette; F V Chisari
Journal:  J Exp Med       Date:  1995-03-01       Impact factor: 14.307
View more
  1 in total

1.  Discovery of Oxime Ethers as Hepatitis B Virus (HBV) Inhibitors by Docking, Screening and In Vitro Investigation.

Authors:  Jie Tan; Min Zhou; Xinhua Cui; Zhuocai Wei; Wanxing Wei
Journal:  Molecules       Date:  2018-03-12       Impact factor: 4.411
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.